Vanguard Group Inc. Has $237.05 Million Holdings in Amicus Therapeutics, Inc. $FOLD

Key Points

• Vanguard Group Inc. has reduced its holdings in Amicus Therapeutics by 0.7%, selling 208,342 shares and now owning approximately 29 million shares valued at $237 million.
• Several hedge funds have increased their stakes in Amicus Therapeutics, with Allspring Global Investments growing its position by 53.7% in the first quarter.
• Analysts have mixed ratings on Amicus Therapeutics, with UBS raising its target price from $21 to $22 and Goldman Sachs lowering it from $12 to $9, resulting in a consensus rating of "Moderate Buy."

Vanguard Group Inc. trimmed its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 0.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,050,621 shares of the biopharmaceutical company's stock after selling 208,342 shares during the period. Vanguard Group Inc. owned approximately 9.43% of Amicus Therapeutics worth $237,053,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Legacy Capital Group California Inc. grew its holdings in Amicus Therapeutics by 16.2% in the 1st quarter. Legacy Capital Group California Inc. now owns 26,993 shares of the biopharmaceutical company's stock valued at $220,000 after buying an additional 3,764 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Amicus Therapeutics by 211.4% in the first quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 3,497 shares during the last quarter. Jefferies Financial Group Inc. acquired a new stake in shares of Amicus Therapeutics in the first quarter worth $1,533,000. XTX Topco Ltd increased its position in Amicus Therapeutics by 177.1% during the first quarter. XTX Topco Ltd now owns 106,773 shares of the biopharmaceutical company's stock worth $871,000 after acquiring an additional 68,245 shares during the period. Finally, Mackenzie Financial Corp raised its stake in Amicus Therapeutics by 89.4% during the 1st quarter. Mackenzie Financial Corp now owns 42,605 shares of the biopharmaceutical company's stock valued at $348,000 after purchasing an additional 20,107 shares during the last quarter.

Analysts Set New Price Targets

Several analysts have issued reports on FOLD shares. The Goldman Sachs Group decreased their price target on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. UBS Group lifted their target price on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Wall Street Zen upgraded Amicus Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, Morgan Stanley upgraded Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research report on Thursday, July 17th. Eight research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $16.22.

Amicus Therapeutics Price Performance

FOLD traded up $0.20 during midday trading on Thursday, reaching $7.60. 3,423,589 shares of the company's stock were exchanged, compared to its average volume of 3,880,773. The company has a quick ratio of 2.29, a current ratio of 3.21 and a debt-to-equity ratio of 1.92. The business has a 50-day simple moving average of $6.29 and a two-hundred day simple moving average of $7.23. The firm has a market capitalization of $2.34 billion, a price-to-earnings ratio of -63.33 and a beta of 0.53. Amicus Therapeutics, Inc. has a one year low of $5.51 and a one year high of $12.65.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.